Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: Application to the analysis of ranitidine and its metabolites in human volunteers

Ashiru, Diane A. I.; Patel, Rajesh; Basit, Abdul W.

doi:10.1016/j.jchromb.2007.10.029

Cited by 70 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A literature survey retrieved a large number of references reporting analytical methods for the determination of these compounds. Mainly separation techniques such as Gas Chromatography (GC) [2], High Performance Thin Layer Chromatography (HPTLC) [3][4][5][6][7][8][9][10], Capillary Electrophoresis (CE) [11][12][13][14][15][16][17] and High Performance Liquid Chromatography (HPLC) [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] have been used, with the latter being the predominant technique for the determination of these compounds in a variety of matrices, utilizing different methods of sample pretreatment and detection modes. HPLC with ultra-violet (UV) detection, employing reversed phase particle packed columns, is most frequently used for the analysis of these drugs in pharmaceutical preparations and biological fluids.…”

Section: Introductionmentioning

confidence: 99%

Use of a monolithic column for the development and validation of a HPLC method for the determination of famotidine, cimetidine and nizatidine in biological fluids

Κοντού¹,

Zotou²

2017

J Appl Bioanal

View full text Add to dashboard Cite

A simple and selective HPLC method, using a monolithic column, was developed for the simultaneous determination of the histamine H 2 -receptor antagonists: famotidine, cimetidine and nizatidine, in the presence of sulfadimethoxine as internal standard. The separation was performed on a Chromolith Performance RP-18 column (100 mm x 4.6 mm i.d.) with an isocratic mobile phase consisting of 0.05 mol/L acetate buffer (adjusted to pH 6.5 with triethylamine)/methanol/ acetonitrile (85:10:5, v/v/v). The wavelength was set at 230 nm. Linearity was obtained for concentrations between 0.2 to 50 μg/mL and limits of detection were in the range 0.07-0.17 μg/mL. Full validation with respect to linearity, selectivity, detection and quantification limits, accuracy, precision and robustness, the latter using the Youden's test, was carried out. The method was successfully applied to the determination of the drugs in human serum and urine following solid phase extraction. Average recoveries between 88.0 to 104.4% and 88.0 to 108.0% in serum and urine samples, respectively, were obtained.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of a monolithic column for the development and validation of a HPLC method for the determination of famotidine, cimetidine and nizatidine in biological fluids

Κοντού¹,

Zotou²

2017

J Appl Bioanal

View full text Add to dashboard Cite

show abstract

“…Some liquid chromatography (LC) methods are available for the determination of nizatidine in biological fluids. [5][6][7][8] Literature reported the HPLC analysis for famotidine, ranitidine, cimetidine and nizatidine in drug products and stability indicating LC method for nizatidine and its impurities. 9,10 Nizatidine monograph is also listed in United States Pharmacopoiea (USP) 11 and European Pharmacopoeia (Eur.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a novel stability indicating RP-UPLC method for simultaneous determination of nizatidine, methylparaben and propylparaben in oral liquid pharmaceutical formulation

Kumar¹,

Vaghela²,

Reddy³

et al. 2012

Quím. Nova

View full text Add to dashboard Cite

Recebido em 24/8/11; aceito em 12/10/11; publicado na web em 4/1/12 A selective and accurate stability-indicating gradient reverse phase ultra performance liquid chromatographic method has been developed and validated for the simultaneous determination of nizatidine, methylparaben and propylparaben in pharmaceutical oral liquid formulation. The separation was achieved on Acquity UPLC TM HSS T3 1.8 µm column by using mobile phase containing a gradient mixture of solvent A (0.02 Mol L -1 KH 2 PO 4 , pH 7.5) and B (60:40 v/v mixture of methanol and acetonitrile) at flow rate of 0.4 mL min -1. Drug product was exposed to the stress conditions of oxidative, acid, base, hydrolytic, thermal and photolytic degradation. The developed method was validated as per international ICH guidelines with respect to specificity, linearity, accuracy, precision and robustness.

show abstract

“…The use of quinoxaline as internal standard and Nemutlue et al 20 published simultaneous separation and determination of seven quinolones using HPLC: analysis of levofloxacin and moxifloxacin in plasma and amniotic fluid. While Diane et al 21 reported simultaneous determination of H 2 receptor antagonists in urine sample.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous determination of moxifloxacin and H2 receptor antagonist in pharmaceutical dosage formulations by RP-HPLC: application to in vitro drug interactions

et al. 2011

View full text Add to dashboard Cite

Recebido em 17/3/10; aceito em 22/9/10; publicado na web em 26/1/11Simultaneous determination of moxifloxacin (MOX) and H 2 -antagonists was first time developed in bulk and formulations. Purospher STAR C 18 (250 x 4.6 mm, 5 mm) column was used. The mobile phase (methanol: water: ACN, 60:45:5 v/v/v, pH 2.7) was delivered at a flow rate of 1.0 mL min -1 , eluent was monitored at 236, 270 and 310 nm for cimetidine, famotidine and ranitidine, respectively. The proposed method is specific, accurate (98-103%), precise (intra-day and inter-day variation 0.098-1.970%) and linear (r>0.998). The LOD and LOQ were 0.006-0.018 and 0.019-0.005 µg mL -1 , respectively. The statistical parameters were applied to verify the results. The method is applicable to routine analysis of formulations and interaction of MOX with H 2 -antagonist.

show abstract

Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: Application to the analysis of ranitidine and its metabolites in human volunteers

Cited by 70 publications

References 26 publications

Use of a monolithic column for the development and validation of a HPLC method for the determination of famotidine, cimetidine and nizatidine in biological fluids

Use of a monolithic column for the development and validation of a HPLC method for the determination of famotidine, cimetidine and nizatidine in biological fluids

Development and validation of a novel stability indicating RP-UPLC method for simultaneous determination of nizatidine, methylparaben and propylparaben in oral liquid pharmaceutical formulation

Simultaneous determination of moxifloxacin and H2 receptor antagonist in pharmaceutical dosage formulations by RP-HPLC: application to in vitro drug interactions

Contact Info

Product

Resources

About